Now Playing
Opinion|Videos|November 26, 2024
The Role of Testing for C Difficile in Clinical Practice
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Testing for C. difficile is indicated in patients with diarrhea, especially after antibiotic use or healthcare exposure.
- Early testing facilitates prompt diagnosis and management, influencing treatment initiation timing.
Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors such as recent antibiotic use, hospitalization, or older age, and how empiric treatment should be initiated while awaiting test results if there is high clinical suspension.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In which patients do you test for C difficile before treating?
- Does the timing of the testing influence when you start treatment?
Advertisement
Related to this article
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Advertisement
Advertisement